As of 2025-05-18, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -0.65. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 88.58 mil USD. NKTR's TTM EBITDA according to its financial statements is -136.65 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 12.2x | 9.9x |
| Forward P/E multiples | 10.4x - 16.8x | 13.8x |
| Fair Price | (7.41) - (8.75) | (8.47) |
| Upside | -1182.1% - -1377.2% | -1337.0% |
| Date | EV/EBITDA |
| 2025-05-14 | -0.69 |
| 2025-05-13 | -0.68 |
| 2025-05-12 | -0.69 |
| 2025-05-09 | -0.52 |
| 2025-05-08 | -0.56 |
| 2025-05-07 | -0.54 |
| 2025-05-06 | -0.59 |
| 2025-05-05 | -0.65 |
| 2025-05-02 | -0.74 |
| 2025-05-01 | -0.78 |
| 2025-04-30 | -0.80 |
| 2025-04-29 | -0.72 |
| 2025-04-28 | -0.74 |
| 2025-04-25 | -0.77 |
| 2025-04-24 | -0.72 |
| 2025-04-23 | -0.65 |
| 2025-04-22 | -0.62 |
| 2025-04-21 | -0.57 |
| 2025-04-17 | -0.58 |
| 2025-04-16 | -0.54 |
| 2025-04-15 | -0.58 |
| 2025-04-14 | -0.54 |
| 2025-04-11 | -0.56 |
| 2025-04-10 | -0.40 |
| 2025-04-09 | -0.41 |
| 2025-04-08 | -0.39 |
| 2025-04-07 | -0.38 |
| 2025-04-04 | -0.47 |
| 2025-04-03 | -0.53 |
| 2025-04-02 | -0.61 |
| 2025-04-01 | -0.58 |
| 2025-03-31 | -0.64 |
| 2025-03-28 | -0.72 |
| 2025-03-27 | -0.75 |
| 2025-03-26 | -0.81 |
| 2025-03-25 | -0.86 |
| 2025-03-24 | -0.89 |
| 2025-03-21 | -0.89 |
| 2025-03-20 | -0.90 |
| 2025-03-19 | -0.94 |
| 2025-03-18 | -0.91 |
| 2025-03-17 | -0.95 |
| 2025-03-14 | -0.94 |
| 2025-03-13 | -0.83 |
| 2025-03-12 | -0.83 |
| 2025-03-11 | -0.83 |
| 2025-03-10 | -0.83 |
| 2025-03-07 | -0.91 |
| 2025-03-06 | -0.89 |
| 2025-03-05 | -0.88 |